The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.

  • The Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S. 1224) would make it illegal for drug makers to use “sham” citizen petitions to delay or keep low-cost generic competitors off the market.
  •  The Prescription Pricing for the People Act (S. 1227) would require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations.
  •  The Preserving Access to Cost Effective Drugs Act (S. 440) would prohibit patent owners from asserting sovereign immunity as a defense in certain actions before the U.S. Patent and Trademark Office to prevent production of generic medications.
  •  The Affordable Prescriptions for Patients Act (S. 1416) would amend the FTC Act to prohibit anticompetitive behaviors by drug product manufacturers, among other provisions. 

These bills could be combined with drug pricing proposals from the Senate Health, Education, Labor and Pensions Committee and Senate Finance Committee. 

Related News Articles

Headline
The House of Representatives last night voted 419-6 to pass legislation (H.R. 748) that would repeal the 40% excise tax on high-value employer-sponsored health…
Headline
The ERISA Industry Committee has withdrawn its support for legislation approved yesterday by the House Energy and Commerce Committee to address surprise…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
Congress should pass legislation that would protect patients from surprise medical bills; preserve the ability of providers and insurers to negotiate private…
Headline
The House Energy and Commerce Subcommittee on Health today passed the No Surprises Act (H.R. 3630), bipartisan legislation that would prohibit balance billing…
Headline
The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-…